NCT04388384 2025-08-06
ELEANOR
Pierre Fabre Pharma GmbH
Completed
Clinical Trials
4 trialsNCT07019272 2025-06-13
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Hebei Medical University Fourth Hospital
Not yet recruiting
NCT06693024 2024-11-20
NeraHER2
Peking University People's Hospital
Recruiting
NCT05491057 2022-08-08
Treatment Patterns of Neratinib in HER2+ EBC in China
Pierre Fabre Medicament
Not yet recruiting